Rchr
J-GLOBAL ID：201601010729843198
Update date: Nov. 03, 2024
Onuki Ritsuko
オヌキリツコ | Onuki Ritsuko
Affiliation and department：
Job title：
Research Scientist
Other affiliations (1)：
-
National Cancer Center, Research Institute, Bioinformatics Division
External Researcher
Research field (2)：
Systems genomics
, Statistical science
Research keywords (1)：
Bioinformatics
Papers (11)：
-
Ryu Okada, Hisanori Takenobu, Shunpei Satoh, Ryuichi P. Sugino, Ritsuko Onuki, Masayuki Haruta, Kyosuke Mukae, Atsuko Nakazawa, Jesmin Akter, Miki Ohira, et al. L3MBTL2 maintains MYCN-amplified neuroblastoma cell proliferation through silencing NRIP3 and BRME1 genes. Genes to Cells. 2024
-
HIROTAKA FUCHIZAWA, KIYOHIRO ANDO, NORIKO MOTOI, TOSHIHIKO IIZUKA, MASAHARU INOUE, KOUKI MITANI, YUTA SANO, HISANORI TAKENOBU, MASAYUKI HARUTA, RITSUKO ONUKI, et al. STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer. Anticancer Research. 2024. 44. 5. 1925-1930
-
Kiyohiro Ando, Ryo Kurashina, Noriko Motoi, Toshihiko Iizuka, Masaharu Inoue, Riko Maruyama, Kouki Mitani, Hisanori Takenobu, Masayuki Haruta, Ritsuko Onuki, et al. Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma. Biochemical and Biophysical Research Communications. 2023. 676. 165-170
-
RYO KURASHINA, KIYOHIRO ANDO, MASAHARU INOUE, RIKO MARUYAMA, KOUKI MITANI, HISANORI TAKENOBU, MASAYUKI HARUTA, RITSUKO ONUKI, YOH MATSUOKA, TAKEHIKO KAMIJO, et al. Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma. Cancer Diagnosis & Prognosis. 2023. 3. 2. 230-235
-
Motoo Nagane, Koichi Ichimura, Ritsuko Onuki, Daichi Narushima, Mai Honda-Kitahara, Kaishi Satomi, Arata Tomiyama, Yasuhito Arai, Tatsuhiro Shibata, Yoshitaka Narita, et al. Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study. Cancers. 2022. 14. 5522
ｍore...
MISC (1)：
-
Koichi Ichimura, Motoo Nagane, Mamoru Kato, Yoshitaka Narita, Tomokazu Aoki, Shota Tanaka, Akitake Mukasa, Toshihiko Wakabayashi, Takeo Uzuka, Hideo Nakamura, et al. BIOMARK: A PHASE II STUDY OF BEVACIZUMAB BEYOND PROGRESSION FOR NEWLY DIAGNOSED GLIOBLASTOMA: SAFETY, EFFICACY AND PROSPECTIVE BIOMARKER ANALYSIS. NEURO-ONCOLOGY. 2019. 21. 12-13
Lectures and oral presentations (12)：
-
Deep Learning for Mutation Detection in Comprehensive Genomic Profiling and its Evaluation
(1st Asia & Pacific Bioinformatics Joint Conference 2024 2024)
-
Development of Cancer Mutation Visualization Tools for Large Samples
(The 82nd Annual Meeting of the Japan Cancer Association 2023)
-
Informatics in Cancer Genome Research
(Informatics in Biology, Medicine and Pharmacology 2023 2023)
-
Deep Learning for Mutation Detection in Cancer Genome Medicine
(The 81st Annual Meeting of the Japanese Cancer Association 2022)
-
Dissecting intratumoral heterogeneity of central nervous system non-germinomatous germ cell tumors by snRNA-seq
(2021)
ｍore...
Professional career (1)：
Return to Previous Page
